脂肪性肝炎
脂肪肝
医学
肝硬化
疾病
脂肪变性
肝活检
组学
金标准(测试)
重症监护医学
模式
病理
内科学
生物信息学
活检
生物
社会科学
社会学
作者
Eirini Martinou,Marinos Pericleous,Irena Stefanova,Vasha Kaur,Angeliki M. Angelidi
出处
期刊:Diagnostics
[MDPI AG]
日期:2022-02-04
卷期号:12 (2): 407-407
被引量:38
标识
DOI:10.3390/diagnostics12020407
摘要
Non-Alcoholic Fatty Liver Disease (NAFLD) is currently the most common cause of chronic liver disease worldwide, and its prevalence is increasing globally. NAFLD is a multifaceted disorder, and its spectrum includes steatosis to steatohepatitis, which may evolve to advanced fibrosis and cirrhosis. In addition, the presence of NAFLD is independently associated with a higher cardiometabolic risk and increased mortality rates. Considering that the vast majority of individuals with NAFLD are mainly asymptomatic, early diagnosis of non-alcoholic steatohepatitis (NASH) and accurate staging of fibrosis risk is crucial for better stratification, monitoring and targeted management of patients at risk. To date, liver biopsy remains the gold standard procedure for the diagnosis of NASH and staging of NAFLD. However, due to its invasive nature, research on non-invasive tests is rapidly increasing with significant advances having been achieved during the last decades in the diagnostic field. New promising non-invasive biomarkers and techniques have been developed, evaluated and assessed, including biochemical markers, imaging modalities and the most recent multi-omics approaches. Our article provides a comprehensive review of the currently available and emerging non-invasive diagnostic tools used in assessing NAFLD, also highlighting the importance of accurate and validated diagnostic tools.
科研通智能强力驱动
Strongly Powered by AbleSci AI